Septal reduction therapy in obstructive hypertrophic cardiomyopathy: contextualizing outcomes in an era of cardiac myosin inhibition
Anirudh Govind · 2026
Read Septal reduction therapy in obstructive hypertrophic cardiomyopathy: contextualizing outcomes in an era of cardiac myosin inhibition by Anirudh Govind (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13273410.txt.
Description
Anirudh Govind published a letter in 2026 that comments on a large Swiss study of septal reduction therapy for a thickened heart muscle condition. The Swiss team tracked people across the whole country after the treatment, which eases a blockage inside the heart. Their results looked strong, and new heart drugs have since changed how doctors think about care.
Govind raises four points that may change how the results should be read. The comparison group was likely sicker, which can inflate the apparent benefit. Pooling two unlike procedures may hide real gaps between them. Leaving out early deaths can understate risk. He also notes the study predates wide use of the new drugs.
Catalog record
| CREATOR | Anirudh Govind |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |